COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00043953
Recruitment Status : Completed
First Posted : August 19, 2002
Last Update Posted : September 27, 2007
Information provided by:

Brief Summary:
The objectives of this study are to explore the metabolic toxicities associated with lopinavir/ritonavir (LPV/r) plus saquinavir mesylate (INV) versus LPV/r plus Combivir in antiretroviral naïve subjects and to assess the overall safety, tolerability and efficacy of LPV/r plus INV versus LPV/r plus Combivir in antiretroviral naïve subjects and to assess the pharmacokinetics of 400 mg INV taken twice a day (BID), 600 mg INV BID and 800 mg INV BID in combination with 400 mg lopinavir/100 mg ritonavir plus 150 mg lamivudine/300 mg zidovudine BID.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Lopinavir/ritonavir Drug: Saquinavir mesylate Drug: Lamivudine/zidovudine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects
Study Start Date : August 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Primary Outcome Measures :
  1. Proportion of subjects with plasma HIV RNA level below 50 copies/mL [ Time Frame: 48 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is naïve to antiretroviral treatment (subjects may not have more than 7 days of any antiretroviral treatment).
  • Subject is at least 18 years of age, inclusive.
  • If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control:condoms, sponge, foams, jellies, diaphragm or intrauterine device(IUD), a vasectomized partner, total abstinence from sexual intercourse
  • If female, the results of a urine pregnancy test performed at screening (urine specimen obtained no earlier than 28 days prior to study drug administration) is negative.
  • Subject is not breast-feeding.
  • Vital signs, physical examination and laboratory results do not exhibit evidence of acute illness.
  • Subject has no significant history of cardiac, renal, neurologic, psychiatric, oncologic, endocrinologic, metabolic or hepatic disease that would in the opinion of the investigator adversely affect his/her participating in this study.
  • Subject does not require and agrees not to take any of the following medications for the duration of the study: midazolam, triazolam, terfenadine, astemizole, cisapride, pimozide, propafenone, flecainide, certain ergot derivatives (ergotamine, dihydroergotamine, ergonovine, and methylergonovine), rifampin, lovastatin, simvastatin, and St. John's wort.
  • Subject agrees not to take any medication during the study, including over-the-counter medicine, alcohol or recreational drugs without the knowledge and permission of the principal investigator.
  • Subject has not been treated for an active AIDS-defining opportunistic infection within 30 days of screening.
  • Subject has a plasma HIV RNA level of greater than 400 copies/mL at screening.
  • Subject agrees to take all doses of the study drug from the bottles provided by the sponsor (rather than other containers, i.e., "pill box").
  • Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed.

Exclusion Criteria:

  • Subject has a history of an allergic reaction or significant sensitivity to LPV/r, INV or Combivir.
  • Subject has a history of substance abuse or psychiatric illness that could preclude adherence with the protocol.
  • Screening laboratory analyses show any of the following abnormal laboratory results:

    • Hemoglobin ≤ 10.0 g/dL
    • Absolute neutrophil count ≤ 1000 cells/µL
    • Platelet count ≤ 50,000 per mL
    • ALT or AST ≥ 3.0 x Upper Limit of Normal (ULN)
    • Creatinine ≥ 1.5 x Upper Limit of Normal (ULN)
  • Subject has received any investigational drug within 30 days prior to study drug administration.
  • For any reason, subject is considered by the investigator to be an unsuitable candidate for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00043953

Layout table for location information
United States, California
AHF Research
Los Angeles, California, United States, 90015
Stephen Becker, MD
San Francisco,, California, United States, 94115
Pacific Horizon Medical Group
San Francisco, California, United States, 94115
Harbor UCLA, Research & Education Institute
Torrance, California, United States, 90502
United States, Massachusetts
Community Research Initiative of New England
Boston,, Massachusetts, United States, 02215
Community Research Initiative of New England
Springfield, Massachusetts, United States, 01107
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill,, North Carolina, United States, 27599
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599-7215
Duke University Medical Center
Durham, North Carolina, United States, 27710
University of Ottawa at the Ottawa Health Research Institute
Ottawa,, Canada, K1H 8L6
University of Ottawa Health Research Institute
Ottawa, Canada, K1H 8L6
Sponsors and Collaborators
Layout table for investigator information
Study Director: Barbara A da Silva, M.D. Associate Medical Director, Antiviral Global Project Team
Layout table for additonal information Identifier: NCT00043953    
Other Study ID Numbers: M01-384
First Posted: August 19, 2002    Key Record Dates
Last Update Posted: September 27, 2007
Last Verified: September 2007
Keywords provided by Abbott:
treatment naive
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Lamivudine, zidovudine drug combination
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors